Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Beta-blocker use not linked to improved breast cancer prognosis

Publish date:: June 5, 2020

Key clinical point: There is no significant association between use of beta-blockers and improved clinical outcomes in women with breast cancer.

Major finding: Beta-blocker use was not associated with breast cancer recurrence (risk ratio [RR], 0.85; P = .17), breast-cancer-related mortality (RR, 0.83; P = .14), and all-cause mortality (RR, 1.01; P = .91).

Study details: A meta-analysis of 17 observational studies including 75,074 patients with breast cancer.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Citation:

Li C et al. Biosci Rep. 2020 May 21. doi: 10.1042/BSR20200721.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,